Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Diacylglycerol kinase theta (DGKQ) is an enzyme that phosphorylates diacylglycerol (DAG) to generate phosphatidic acid (PA), acting as a central regulatory switch between signaling pathways mediated by these two important lipid second messengers. The protein contains cysteine-rich domains, a proline-rich region, and a pleckstrin homology domain with an overlapping Ras-associating domain, and is localized to the nuclear speckle domains. DGKQ is implicated in various biological processes, including the regulation of the phosphatidylinositol cycle during cell signal transduction, synaptic vesicle endocytosis, and steroidogenic gene transcription, with documented disease associations such as retinal degeneration and postural kyphosis[1][2][3][7].
Catalytic conversion of diacylglycerol (DAG) to phosphatidic acid (PA), modulating levels of these second messengers with downstream effects on signaling pathways
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Diacylglycerol kinase theta (DGKQ).